Jane Street’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$351K Buy
2,034
+25
+1% +$4.63K ﹤0.01% 8872
2025
Q4
$401K Buy
2,009
+656
+48% +$119K ﹤0.01% 8191
2025
Q3
$212K Sell
1,353
-38,075
-97% -$6.05M ﹤0.01% 9565
2025
Q2
$5.98M Sell
39,428
-98,017
-71% -$13.1M ﹤0.01% 2769
2025
Q1
$20.7M Buy
137,445
+101,109
+278% +$17M 0.01% 1265
2024
Q4
$6.71M Buy
36,336
+4,620
+15% +$890K ﹤0.01% 2307
2024
Q3
$6.25M Buy
31,716
+9,299
+41% +$1.93M ﹤0.01% 2505
2024
Q2
$4.63M Buy
22,417
+5,280
+31% +$1.2M ﹤0.01% 3081
2024
Q1
$4.64M Buy
17,137
+2,189
+15% +$523K ﹤0.01% 2725
2023
Q4
$3.53M Sell
14,948
-1,363
-8% -$268K ﹤0.01% 3368
2023
Q3
$3.2M Sell
16,311
-8,764
-35% -$1.8M ﹤0.01% 3277
2023
Q2
$5.27M Buy
25,075
+2,962
+13% +$589K ﹤0.01% 2660
2023
Q1
$4.46M Buy
22,113
+4,806
+28% +$1.09M ﹤0.01% 2605
2022
Q4
$3.77M Buy
17,307
+4,807
+38% +$1.05M ﹤0.01% 2872
2022
Q3
$2.46M Buy
+12,500
New +$2.7M ﹤0.01% 3829
2022
Q2
Sell
-8,376
Closed -$2.05M 9781
2022
Q1
$2.38M Buy
8,376
+1,562
+23% +$482K ﹤0.01% 4415
2021
Q4
$2.57M Buy
6,814
+644
+10% +$250K ﹤0.01% 3983
2021
Q3
$2.55M Sell
6,170
-4,597
-43% -$1.91M ﹤0.01% 3984
2021
Q2
$3.98M Buy
10,767
+4,824
+81% +$1.61M ﹤0.01% 3045
2021
Q1
$1.72M Buy
5,943
+201
+4% +$55.9K ﹤0.01% 4315
2020
Q4
$1.44M Sell
5,742
-6,364
-53% -$1.52M ﹤0.01% 4072
2020
Q3
$2.74M Buy
12,106
+10,780
+813% +$2.24M ﹤0.01% 2566
2020
Q2
$231K Buy
+1,326
New +$212K ﹤0.01% 6192
2020
Q1
Sell
-3,628
Closed -$554K 5366
2019
Q4
$554K Sell
3,628
-2,434
-40% -$337K ﹤0.01% 3570
2019
Q3
$802K Buy
6,062
+2,832
+88% +$380K ﹤0.01% 2909
2019
Q2
$458K Buy
+3,230
New +$438K ﹤0.01% 3691
2019
Q1
Sell
-1,977
Closed -$224K 5074
2018
Q4
$224K Sell
1,977
-11,332
-85% -$1.42M ﹤0.01% 4377
2018
Q3
$1.79M Buy
13,309
+8,025
+152% +$990K ﹤0.01% 2029
2018
Q2
$593K Buy
+5,284
New +$571K ﹤0.01% 3404
2017
Q4
Sell
-2,416
Closed -$261K 4632
2017
Q3
$261K Buy
+2,416
New +$248K ﹤0.01% 3847
2017
Q1
Sell
-13,077
Closed -$996K 4189
2016
Q4
$996K Buy
13,077
+10,038
+330% +$762K ﹤0.01% 2080
2016
Q3
$253K Buy
+3,039
New +$255K ﹤0.01% 3470
2016
Q2
Sell
-5,225
Closed -$397K 4122
2016
Q1
$397K Sell
5,225
-37,765
-88% -$2.8M ﹤0.01% 2861
2015
Q4
$3.46M Buy
42,990
+28,554
+198% +$2.06M 0.02% 681
2015
Q3
$917K Buy
+14,436
New +$1.04M 0.01% 1708
2015
Q2
Sell
-8,270
Closed -$656K 3665
2015
Q1
$656K Buy
+8,270
New +$610K 0.01% 1764
2014
Q2
Sell
-10,859
Closed -$655K 2617
2014
Q1
$655K Buy
+10,859
New +$633K 0.01% 1323
2013
Q4
Sell
-50,008
Closed -$2.31M 2413
2013
Q3
$2.31M Buy
50,008
+36,784
+278% +$1.69M 0.03% 506
2013
Q2
$543K Buy
+13,224
New +$567K 0.01% 1375

Other funds holding CRL

Jane Street's CRL Position: Q1 2026 in Review

Jane Street increased its Charles River Laboratories (CRL) stake by 1.2% in Q1 2026, buying an estimated $4.63K and bringing the position to 2,034 shares worth $351K. The position accounts for ﹤0.01% of the portfolio, ranked #8872.

Jane Street first reported a position in CRL in Q2 2013 and has held it in 39 quarters since. The position peaked at $20.7M in Q1 2025. 558 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Jane Street held 2,034 shares of Charles River Laboratories worth $351K as of Q1 2026.
  • Jane Street bought 25 Charles River Laboratories shares in Q1 2026, an estimated $4.63K.
  • Charles River Laboratories made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #8872 holding.
  • Jane Street first reported a position in Charles River Laboratories in Q2 2013 and has held it in 39 quarters since.
  • Jane Street's Charles River Laboratories position peaked at $20.7M in Q1 2025.
  • 558 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.